Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo

Abstract

BackgroundPaeoniflorin (PF), a glucoside isolated from the dried root of Paeonia lactiflora Pall, has been reported to have a number of pharmacological properties, including immunity-regulation, anticancer activities, and neuroprotective effect. However, PF’s pharmacological role in bone disorder has been seldom reported. Hence, this study was designed to investigate the effects of PF on osteoclast differentiation and osteolysis diseases.Material/MethodsThe bone marrow macrophages were isolated from C57BL/6 mice and incubated with RANK ligand (RANKL) and various concentrations of PF. After 5 days of incubation, tartrate-resistant acid phosphatase (+) cells and bone resorption pits were counted. Effects of PF on expression of osteoclast-specific protein and gene were investigated via Western blot, q-PCR, and immunofluorescence assay. The osteoprotective effect of PF in vivo was evaluated in a calvarial osteolysis model via micro-CT scan and histological stain.ResultsIn vitro, PF intervention inhibited osteoclast formation and resorption activity. PF also impaired RANKL-induced NF-κB phosphorylation and immigration to the nucleus. PF suppressed osteoclast-marker protein and gene expression. In vivo, PF inhibited cobalt-chromium-molybdenum alloy particle-induced osteolysis and reduced osteoclast number in tissue slice.ConclusionsPF is a potential agent against osteolysis-related diseases caused by excessive osteoclast activity.

Effects of Chinese Herbal Medicines on the Risk of Overall Mortality, Readmission, and Reoperation in Hip Fracture Patients

“…Paeoniflorin has a significant anti-inflammatory effect on rheumatoid arthritis (Lai et al, 2018; Xu et al, 2018). Paeoniflorin also shows antiosteoporosis activity and regulates osteoclastogenesis and osteoblastogenesis (Li and Chent 2018b; Wang et al, 2018b).…”

MEDAG expression in vitro and paeoniflorin alleviates bone loss by regulating the MEDAG/AMPK/PPARγ signaling pathway in vivo

“…PF also restored bone microarchitecture which is in line with a previous study [ 25 ], suggesting that PF has a bone protective effect. PF reduced BMD by inhibiting the formation of osteoclasts and resorptions [ 26 ]. It is reported that PF can reduce osteopenia in mice by speeding up mineralization and bone formation [ 21 ].…”

Histopathological and biochemical evaluation of paeoniflorin administration in an experimental periodontitis model

“…Pae suppresses bone resorption and, by stimulating bone formation, has a positive effect on bone metabolism and remodeling [16,17]. Additionally, Pae has been shown to suppress excessive osteoclastic activity [16,18]. Pae has been approved by China's State Food and Drug Administration as a disease-modifying drug in the treatment of rheumatoid arthritis [19].…”